David Leppert

16.6k total citations · 6 hit papers
170 papers, 10.5k citations indexed

About

David Leppert is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Neurology. According to data from OpenAlex, David Leppert has authored 170 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Pathology and Forensic Medicine, 46 papers in Molecular Biology and 43 papers in Neurology. Recurrent topics in David Leppert's work include Multiple Sclerosis Research Studies (80 papers), Skin and Cellular Biology Research (28 papers) and Protease and Inhibitor Mechanisms (22 papers). David Leppert is often cited by papers focused on Multiple Sclerosis Research Studies (80 papers), Skin and Cellular Biology Research (28 papers) and Protease and Inhibitor Mechanisms (22 papers). David Leppert collaborates with scholars based in Switzerland, United States and United Kingdom. David Leppert's co-authors include Jens Kühle, Ludwig Kappos, Christian Barro, Stephen L. Leib, Edward J. Goetzl, Raija L.P. Lindberg, Pascal Benkert, Stephen L. Hauser, Michael J. Banda and Emmanuelle Waubant and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

David Leppert

166 papers receiving 10.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis

2017 819 citations Christian Barro, Pascal Benkert et al. Annals of Neurology profile →
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

2011 538 citations Ludwig Kappos, David Leppert et al. profile →
Serum neurofilament light levels in normal aging and their association with morphologic brain changes

2020 380 citations Michael Khalil, Lukas Pirpamer et al. profile →
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

2019 379 citations Jens Kühle, Harald Kropshofer et al. Neurology profile →
Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

2018 367 citations Christian Barro, Pascal Benkert et al. profile →
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

2013 366 citations Ludwig Kappos, David Leppert et al. profile →

Peers

Countries citing papers authored by David Leppert

Since Specialization

Citations

This map shows the geographic impact of David Leppert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Leppert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Leppert more than expected).

Fields of papers citing papers by David Leppert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Leppert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Leppert. The network helps show where David Leppert may publish in the future.

Co-authorship network of co-authors of David Leppert

This figure shows the co-authorship network connecting the top 25 collaborators of David Leppert. A scholar is included among the top collaborators of David Leppert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Leppert. David Leppert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay 2025 ·Clinica Chimica Acta ·Ronald A. Booth, Daniel R. Beriault, Raphaël Schneider, Pascal Benkert, Eline A.J. Willemse, Aleksandra Maleska Maceski, David Leppert, Mark S. Freedman, Jens Kühle	2
2	Plasma CHI3L1 associates with brain volume loss and glial activation in multiple sclerosis 2025 ·Journal of Neurology Neurosurgery & Psychiatry ·(unknown), Maija Saraste, Marjo Nylund, Markus Matilainen, (unknown), (unknown), (unknown), Sauli Laaksonen, (unknown), Jens Kühle, David Leppert, Tero Soukka, Urpo Lamminmäki, Laura Airas	1
3	Transient Global Amnesia (TGA): Is It Really Benign? A Pilot Study on Blood Biomarkers 2025 ·International Journal of Molecular Sciences ·(unknown), Tobias Moser, (unknown), Michael Khalil, (unknown), (unknown), (unknown), Jens Kühle, David Leppert, Pascal Benkert, Johannes Pfaff, Eugen Trinka, Slaven Pikija	0
4	High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis 2023 ·European Journal of Neurology ·Arabella Buchmann, Lukas Pirpamer, Daniela Pinter, Margarete M. Voortman, (unknown), Alexander Pichler, Aleksandra Maleska Maceski, Pascal Benkert, Gerhard Bachmaier, Stefan Ropele, Markus Reindl, David Leppert, Jens Kühle, Christian Enzinger, Michael Khalil	8
5	Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis 2023 ·Journal of Neurology Neurosurgery & Psychiatry ·David Leppert, Mitsuru Watanabe, Sabine Schaedelin, Fredrik Piehl, Roberto Furlan, Matteo Gastaldi, Jeremy J. Lambert, Björn Evertsson, Katharina Fink, Takuya Matsushita, Katsuhisa Masaki, Noriko Isobe, Jun‐ichi Kira, Pascal Benkert, Aleksandra Maleska Maceski, Eline A.J. Willemse, Johanna Oechtering, Annette Orleth, Stéphanie Meier, Jens Kühle	9
6	Association of serum neurofilament light with microglial activation in multiple sclerosis 2023 ·Journal of Neurology Neurosurgery & Psychiatry ·Maija Saraste, Markus Matilainen, (unknown), (unknown), Marcus Sucksdorff, David Leppert, Jens Kühle, Laura Airas	14
7	Blood Neurofilament Light in Progressive Multiple Sclerosis 2022 ·Neurology ·David Leppert, Harald Kropshofer, Dieter A. Häring, Frank Dahlke, (unknown), Rolf Meinert, Davorka Tomic, Ludwig Kappos, Jens Kühle	33
8	Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS 2021 ·Multiple Sclerosis Journal ·Jens Kühle, Nadia Daizadeh, Pascal Benkert, Aleksandra Maleska Maceski, Christian Barro, Zuzanna Michalak, Maria Pia Sormani, J.F. GODIN, Srinivas Shankara, Tarek A. Samad, Alice K. Jacobs, (unknown), (unknown), (unknown), Colin Mitchell, David Leppert, Evis Havari, Ludwig Kappos	26
9	Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis 2021 ·Brain Communications ·Fay Probert, Tianrong Yeo, Yifan Zhou, Megan Sealey, Siddharth Arora, Jacqueline Palace, Timothy D. W. Claridge, Rainer Hillenbrand, Johanna Oechtering, David Leppert, Jens Kühle, Daniel C. Anthony	15
10	Investigating the Correlation Between Serum Neurofilament Light Chain (sNfL) Concentration and Magnetic Resonance Imaging (MRI)-Outcomes in Patients With a First Clinical Demyelinating Event in the REFLEX Trial (1116) 2021 ·Neurology ·Jens Kühle, David Leppert, Gıancarlo Comı, Nicola De Stefano, Ludwig Kappos, Mark S. Freedman, (unknown), Sanjeev Roy	1
11	Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019 2020 ·Annals of Neurology ·Raoul Sutter, Lisa Hert, Gian Marco De Marchis, Raphael Twerenbold, Ludwig Kappos, Yvonne Naegelin, Gabriela M. Kuster, Pascal Benkert, (unknown), Aleksandra Maleska Maceski, Stephan Rüegg, Martin Siegemund, David Leppert, Sarah Tschudin‐Sutter, Jens Kühle	54
12	Ratio and index of Neurofilament light chain indicate its origin in Guillain‐Barré Syndrome 2020 ·Annals of Clinical and Translational Neurology ·Péter Körtvelyessy, Jens Kühle, Emrah Düzel, Stefan Vielhaber, (unknown), (unknown), Frank Leypoldt, Burkhart Schraven, Dirk Reinhold, David Leppert, Alexander Goihl	33
13	Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy 2020 ·Amyloid ·Luı́s F. Maia, Aleksandra Maleska Maceski, Isabel Conceição, Laura Obici, Rui Magalhães, (unknown), David Leppert, Giampaolo Merlini, Jens Kühle, Maria João Saraiva	43
14	Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD 2019 ·Neurology ·Mitsuru Watanabe, Yuri Nakamura, Zuzanna Michalak, Noriko Isobe, Christian Barro, David Leppert, Takuya Matsushita, Fumie Hayashi, Ryo Yamasaki, Jens Kühle, Jun‐ichi Kira	161
15	Blood neurofilament light as a potential endpoint in Phase 2 studies in MS 2019 ·Annals of Clinical and Translational Neurology ·Maria Pia Sormani, Dieter Haering, Harald Kropshofer, David Leppert, Uma Kundu, Christian Barro, Ludwig Kappos, Davorka Tomic, Jens Kühle	42
16	Including Blood Neurofilament Light Chain in the NEDA Concept in Relapsing–Remitting Multiple Sclerosis Trials (S24.007) 2018 ·Neurology ·Maria Pia Sormani, Ludwig Kappos, Dieter A. Häring, Harald Kropshofer, Christian Barro, David Leppert, Davorka Tomic, Jens Kühle	8
17	Composite end points to assess delay of disability progression by MS treatments 2014 ·Multiple Sclerosis Journal ·(unknown), Emmanuelle Waubant, Gary Cutter, J. S. Wolinsky, David Leppert	25
18	AUY954, a selective S1P1 modulator, prevents experimental autoimmune neuritis 2009 ·Journal of Neuroimmunology ·Zhiyuan Zhang, (unknown), Zhiren Zhang, (unknown), Barbara Nuesslein‐Hildesheim, David Leppert, Hermann J. Schluesener	40
19	Oral fingolimod (FTY720) therapy reduces blood brain barrier breakdown, microglial activation, and leukocyte recruitment in a focal DTH model of multiple sclerosis 2009 ·Multiple Sclerosis Journal ·Daniel C. Anthony, Nicola R. Sibson, (unknown), Daniela Piani, David Leppert	1
20	Cardiac arrest during partial seizure 2000 ·Neurology ·Peter Fuhr, David Leppert	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact